Montserrat M. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 96 of 267 partner sites.
Specializations
Early Stage Breast Cancer
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative early breast cancer, with particular focus on adjuvant therapeutic approaches. Their research extends to early-stage invasive breast cancer treatment and long-term patient outcomes.
- Neoadjuvant treatment strategies
- Early-stage disease management
- Long-term patient monitoring
Their work encompasses comprehensive evaluation of disease progression and treatment responses in early-stage breast cancer scenarios.
Advanced Breast Cancer
The investigator conducts research in advanced triple negative breast cancer and metastatic breast disease. They have particular expertise in treating elderly patients with advanced breast cancer, focusing on personalized treatment approaches.
- Triple negative breast cancer therapy
- Geriatric oncology approaches
- Metastatic disease management
Their research includes innovative combination therapies and targeted treatments for advanced disease states.
Precision Medicine
The investigator focuses on biomarker-driven treatment approaches and personalized therapy selection. Their work includes evaluation of recurrence scores and molecular testing to guide treatment decisions.
- Targeted therapy optimization
- Treatment response assessment
- Risk-stratified approaches
Their research emphasizes evidence-based treatment selection using molecular and clinical indicators.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.